For a generation of gay men who came of age in the 1980s and 1990s, becoming sexually active meant confronting the dangers of catching and transmitting HIV. In the 21st century, however, the development of viral suppression treatments and preventative pills such as PrEP and nPEP has massively reduced the risk of acquiring HIV. Yet some of the stigma around gay male promiscuity and bareback sex has remained, inhibiting open dialogues about sexual desire, risk, and pleasure. A Pill for Promiscuity brings together academics, artists, and activists—from different generations, countries, ethnic backgrounds, and HIV statuses—to reflect on how gay sex has changed in a post-PrEP era. Some offer personal perspectives on the value of promiscuity and the sexual communities it fosters, while others critique unequal access to PrEP and the increased role Big Pharma now plays in gay life. With a diverse group of contributors that includes novelist Andrew Holleran, trans scholar Lore/tta LeMaster, cartoonist Steve MacIsaac, and pornographic film director Mister Pam, this book asks provocative questions about how we might reimagine queer sex and sexuality in the 21st century
Zugriffsoptionen:
Die folgenden Links führen aus den jeweiligen lokalen Bibliotheken zum Volltext:
How have Scotland's first post-devolution decades been felt across the political landscape?Features analysis of the key political institutions and parties in ScotlandProvides a detailed chronology of the devolution eraIncludes perspectives from civil servants, campaigners and politicians including Jim Gallagher, Joyce McMillan, Johann Lamont, Murdo Fraser and Marco BiagiIf you want a taster ahead of publication on 1st August you can download the introduction from the resources tab, below.Marking the first twenty years of the Scottish Parliament, this collection of essays assesses its impact on Scotland, the UK and Europe and compares progress against pre-devolution hopes and expectations. It brings together the voices of ministers and advisers, leading political scientists and historians, commentators, journalists and former civil servants – building an authoritative account of what the Scottish Parliament has made of devolution.The Story of the Scottish Parliament is an essential guide to the powers Holyrood may need for Scotland to flourish in an increasingly uncertain world.Contributors to The Story of the Scottish ParliamentMargaret Arnott is professor of public policy at the University of the West of Scotland.Lynn Bennie is reader in politics at the University of Aberdeen. Marco G. Biagi was MSP for Edinburgh from 2011 to 2016, latterly serving as Minister for Local Government and Community Empowerment. Alan Convery is lecturer in politics at the University of Edinburgh. Torcuil Crichton is the Daily Record's Westminster editor and a journalistic veteran of six UK general election campaigns and five Scottish elections. Sir John Curtice is professor of politics at Strathclyde University and senior research fellow, NatCen/ScotCen Social Research. Zoe Ferguson is an associate with the Carnegie UK Trust and has been developing their work on kindness. Murdo Fraser is MSP for Mid Scotland and Fife and was deputy leader of the Scottish Conservative and Unionist Party from 2005 to 2011.Jim Gallagher's 35-year civil service career included heading the Scottish Justice department, being private secretary to two Secretaries of State for Scotland, and twice serving in the No 10 Policy Unit under different Prime Ministers. Ewan Gibbs lectures in sociology and social policy at the University of the West of Scotland and sits on the committee of the Scottish Labour History Society. Ambrose Gillick is a designer and lecturer in architecture at Kent School of Architecture. David Gow is now editor of Social Europe and of sceptical.scot. Gerry Hassan is research fellow in contemporary history at Dundee University. Ailsa Henderson is professor of political science at the University of Edinburgh where she conducts research on comparative sub-state political behaviour and political culture.Kirsty Hughes is director of the Scottish Centre on European Relations. Lee Ivett is an award-winning architect, designer and founding director of Baxendale Studio. Richard Kerley is Emeritus Professor of Management at Queen Margaret University, Edinburgh, and co-chair of the Centre for Scottish Public Policy. Colin Kidd is Wardlaw Professor of Modern History at the University of St Andrews. Johann Lamont is Labour MSP for Glasgow and was previously leader of the Scottish Labour Party.Craig McAngus is a lecturer in politics at the University of the West of Scotland. Neil McGarvey is a senior teaching fellow in the School of Government and Public Policy at the University of Strathclyde, Glasgow. Joyce McMillan is a freelance
Zugriffsoptionen:
Die folgenden Links führen aus den jeweiligen lokalen Bibliotheken zum Volltext:
AbstractIntroductionAdolescents living with HIV are subject to multiple co‐morbidities, including growth retardation and immunodeficiency. We describe growth and CD4 evolution during adolescence using data from the Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) global project.MethodsData were collected between 1994 and 2015 from 11 CIPHER networks worldwide. Adolescents with perinatally acquired HIV infection (APH) who initiated antiretroviral therapy (ART) before age 10 years, with at least one height or CD4 count measurement while aged 10–17 years, were included. Growth was measured using height‐for‐age Z‐scores (HAZ, stunting if <‐2 SD, WHO growth charts). Linear mixed‐effects models were used to study the evolution of each outcome between ages 10 and 17. For growth, sex‐specific models with fractional polynomials were used to model non‐linear relationships for age at ART initiation, HAZ at age 10 and time, defined as current age from 10 to 17 years of age.ResultsA total of 20,939 and 19,557 APH were included for the growth and CD4 analyses, respectively. Half were females, two‐thirds lived in East and Southern Africa, and median age at ART initiation ranged from <3 years in North America and Europe to >7 years in sub‐Saharan African regions. At age 10, stunting ranged from 6% in North America and Europe to 39% in the Asia‐Pacific; 19% overall had CD4 counts <500 cells/mm3. Across adolescence, higher HAZ was observed in females and among those in high‐income countries. APH with stunting at age 10 and those with late ART initiation (after age 5) had the largest HAZ gains during adolescence, but these gains were insufficient to catch‐up with non‐stunted, early ART‐treated adolescents. From age 10 to 16 years, mean CD4 counts declined from 768 to 607 cells/mm3. This decline was observed across all regions, in males and females.ConclusionsGrowth patterns during adolescence differed substantially by sex and region, while CD4 patterns were similar, with an observed CD4 decline that needs further investigation. Early diagnosis and timely initiation of treatment in early childhood to prevent growth retardation and immunodeficiency are critical to improving APH growth and CD4 outcomes by the time they reach adulthood.
We present the temperature and polarization angular power spectra of the CMB measured by the Atacama Cosmology Telescope (ACT) from 5400 deg(2) of the 2013-2016 survey, which covers >15000 deg(2) at 98 and 150 GHz. For this analysis we adopt a blinding strategy to help avoid confirmation bias and, related to this, show numerous checks for systematic error done before unblinding. Using the likelihood for the cosmological analysis we constrain secondary sources of anisotropy and foreground emission, and derive a "CMB-only" spectrum that extends to l = 4000. At large angular scales, foreground emission at 150 GHz is similar to 1% of TT and EE within our selected regions and consistent with that found by Planck. Using the same likelihood, we obtain the cosmological parameters for Lambda CDM for the ACT data alone with a prior on the optical depth of tau = 0.065 +/- 0.015. Lambda CDM is a good fit. The best-fit model has a reduced chi(2) of 1.07 (PTE = 0.07) with H-0 = 67.9 +/- 1.5 km/s/Mpc. We show that the lensing BB signal is consistent with Lambda CDM and limit the celestial EB polarization angle to psi(P) = 0.07 degrees +/- 0.09 degrees. We directly cross correlate ACT with Planck and observe generally good agreement but with some discrepancies in TE. All data on which this analysis is based will be publicly released. ; National Science Foundation (NSF) AST0408698 AST-0965625 AST-1440226 PHY0355328 PHY-0855887 PHY-1214379 Princeton University University of Pennsylvania Canada Foundation for Innovation CFI under the Compute Canada Government of Ontario Ontario Research Fund \ Research Excellence University of Toronto Simons Foundation National Aeronautics & Space Administration (NASA) NNX13AE56G NNX14AB58G National Institute of Standards & Technology (NIST) - USA Cornell Presidential Postdoctoral Fellowship Comision Nacional de Investigacion Cientifica y Tecnologica (CONICYT) BASAL CATA AFB-170002 National Science Foundation (NSF) AST-1814971 AST1454881 AST-1513618 AST-1907657 AST-1910021 National Research Foundation - South Africa STFC Ernest Rutherford Fellowship ST/M004856/2 STFC Consolidated Grant ST/S00033X/1 Horizon 2020 ERC Starting Grant 849169 Dicke Fellowship Mishrahi and Wilkinson funds CIfAR's Gravity & the Extreme Universe Program CGIAR Dunlap Institute
The Astropy Project supports and fosters the development of open-source and openly developed Python packages that provide commonly needed functionality to the astronomical community. A key element of the Astropy Project is the core package astropy, which serves as the foundation for more specialized projects and packages. In this article, we provide an overview of the organization of the Astropy project and summarize key features in the core package, as of the recent major release, version 2.0. We then describe the project infrastructure designed to facilitate and support development for a broader ecosystem of interoperable packages. We conclude with a future outlook of planned new features and directions for the broader Astropy Project. ; Google; NumFOCUS; Python Software Foundation; Space Telescope Science Institute; Harvard-Smithsonian Center for Astrophysics; South African Astronomical Observatory; National Aeronautics and Space Administration through the Smithsonian Astrophysical Observatory [SV3-73016]; National Aeronautics Space Administration [NAS8-03060]; UW eScience Institute via Moore Foundation; Sloan Foundation; Washington Research Foundation; NASA's Planetary Astronomy Program; NASA [NAS8-03060, NAS 5-26555]; NASA through Hubble Fellowship - Space Telescope Science Institute [51316.01]; Giacconi Fellowship; FONDECYT [1170618]; MINEDUC-UA [ANT 1655, ANT 1656]; German Research Foundation (DFG) [SFB 881]; German Research Foundation (DFG); NSF [AST-1313484]; Spanish government [AYA2016-75808-R]; Gemini Observatory; Korea Astronomy and Space Science Institute, under the RD program ; The Astropy community is supported by and makes use of a number of organizations and services outside the traditional academic community. We thank Google for financing and organizing the Google Summer of Code (GSoC) program, that has funded several students per year to work on Astropy related projects over the summer. These students often turn into longterm contributors. We also thank NumFOCUS and the Python Software Foundation for financial support. Within the academic community, we thank institutions that make it possible for astronomers and other developers on their staff to contribute their time to the development of Astropy projects. We acknowledge the support of the Space Telescope Science Institute, Harvard-Smithsonian Center for Astrophysics, and the South African Astronomical Observatory.r The following individuals would like to recognize support for their personal contributions. H.M.G. was supported by the National Aeronautics and Space Administration through the Smithsonian Astrophysical Observatory contract SV3-73016 to MIT for Support of the Chandra X-Ray Center, which is operated by the Smithsonian Astrophysical Observatory for and on behalf of the National Aeronautics Space Administration under contract NAS8-03060. J.T.V. was supported by the UW eScience Institute via grants from the Moore Foundation, the Sloan Foundation, and the Washington Research Foundation. S.M.C. acknowledges the National Research Foundation of South Africa. M.V.B. was supported by NASA's Planetary Astronomy Program. T.L.A. was supported by NASA contract NAS8-03060. Support for E.J.T. was provided by NASA through Hubble Fellowship grant No. 51316.01 awarded by the Space Telescope Science Institute, which is operated by the Association of Universities for Research in Astronomy, Inc., for NASA, under contract NAS 5-26555, as well as a Giacconi Fellowship. M.B. was supported by the FONDECYT regular project 1170618 and the MINEDUC-UA projects codes ANT 1655 and ANT 1656. D.H. was supported through the SFB 881 "The Milky Way System" by the German Research Foundation (DFG). W.E.K was supported by an ESO Fellowship. C.M. is supported by NSF grant AST-1313484. S.P. was supported by grant AYA2016-75808-R (FEDER) issued by the Spanish government. J.E.H.T. was supported by the Gemini Observatory, which is operated by the Association of Universities for Research in Astronomy, Inc., on behalf of the international Gemini partnership of Argentina, Brazil, Canada, Chile, and the United States of America. Y.P.B was supported by the Korea Astronomy and Space Science Institute, under the R&D program supervised by the Ministry of Science, ICT, and Future Planning.
Background Surgery is the main modality of cure for solid cancers and was prioritised to continue during COVID-19 outbreaks. This study aimed to identify immediate areas for system strengthening by comparing the delivery of elective cancer surgery during the COVID-19 pandemic in periods of lockdown versus light restriction. Methods This international, prospective, cohort study enrolled 20 006 adult (≥18 years) patients from 466 hospitals in 61 countries with 15 cancer types, who had a decision for curative surgery during the COVID-19 pandemic and were followed up until the point of surgery or cessation of follow-up (Aug 31, 2020). Average national Oxford COVID-19 Stringency Index scores were calculated to define the government response to COVID-19 for each patient for the period they awaited surgery, and classified into light restrictions (index 60). The primary outcome was the non-operation rate (defined as the proportion of patients who did not undergo planned surgery). Cox proportional-hazards regression models were used to explore the associations between lockdowns and non-operation. Intervals from diagnosis to surgery were compared across COVID-19 government response index groups. This study was registered at ClinicalTrials.gov, NCT04384926. Findings Of eligible patients awaiting surgery, 2003 (10·0%) of 20 006 did not receive surgery after a median follow-up of 23 weeks (IQR 16–30), all of whom had a COVID-19-related reason given for non-operation. Light restrictions were associated with a 0·6% non-operation rate (26 of 4521), moderate lockdowns with a 5·5% rate (201 of 3646; adjusted hazard ratio [HR] 0·81, 95% CI 0·77–0·84; p<0·0001), and full lockdowns with a 15·0% rate (1775 of 11 827; HR 0·51, 0·50–0·53; p<0·0001). In sensitivity analyses, including adjustment for SARS-CoV-2 case notification rates, moderate lockdowns (HR 0·84, 95% CI 0·80–0·88; p<0·001), and full lockdowns (0·57, 0·54–0·60; p<0·001), remained independently associated with non-operation. Surgery beyond 12 weeks from diagnosis in patients without neoadjuvant therapy increased during lockdowns (374 [9·1%] of 4521 in light restrictions, 317 [10·4%] of 3646 in moderate lockdowns, 2001 [23·8%] of 11 827 in full lockdowns), although there were no differences in resectability rates observed with longer delays. Interpretation Cancer surgery systems worldwide were fragile to lockdowns, with one in seven patients who were in regions with full lockdowns not undergoing planned surgery and experiencing longer preoperative delays. Although short-term oncological outcomes were not compromised in those selected for surgery, delays and non-operations might lead to long-term reductions in survival. During current and future periods of societal restriction, the resilience of elective surgery systems requires strengthening, which might include protected elective surgical pathways and long-term investment in surge capacity for acute care during public health emergencies to protect elective staff and services. Funding National Institute for Health Research Global Health Research Unit, Association of Coloproctology of Great Britain and Ireland, Bowel and Cancer Research, Bowel Disease Research Foundation, Association of Upper Gastrointestinal Surgeons, British Association of Surgical Oncology, British Gynaecological Cancer Society, European Society of Coloproctology, Medtronic, Sarcoma UK, The Urology Foundation, Vascular Society for Great Britain and Ireland, and Yorkshire Cancer Research.
Background Surgery is the main modality of cure for solid cancers and was prioritised to continue during COVID-19 outbreaks. This study aimed to identify immediate areas for system strengthening by comparing the delivery of elective cancer surgery during the COVID-19 pandemic in periods of lockdown versus light restriction. Methods This international, prospective, cohort study enrolled 20 006 adult (≥18 years) patients from 466 hospitals in 61 countries with 15 cancer types, who had a decision for curative surgery during the COVID-19 pandemic and were followed up until the point of surgery or cessation of follow-up (Aug 31, 2020). Average national Oxford COVID-19 Stringency Index scores were calculated to define the government response to COVID-19 for each patient for the period they awaited surgery, and classified into light restrictions (index 60). The primary outcome was the non-operation rate (defined as the proportion of patients who did not undergo planned surgery). Cox proportional-hazards regression models were used to explore the associations between lockdowns and non-operation. Intervals from diagnosis to surgery were compared across COVID-19 government response index groups. This study was registered at ClinicalTrials.gov, NCT04384926. Findings Of eligible patients awaiting surgery, 2003 (10·0%) of 20 006 did not receive surgery after a median follow-up of 23 weeks (IQR 16–30), all of whom had a COVID-19-related reason given for non-operation. Light restrictions were associated with a 0·6% non-operation rate (26 of 4521), moderate lockdowns with a 5·5% rate (201 of 3646; adjusted hazard ratio [HR] 0·81, 95% CI 0·77–0·84; p<0·0001), and full lockdowns with a 15·0% rate (1775 of 11 827; HR 0·51, 0·50–0·53; p<0·0001). In sensitivity analyses, including adjustment for SARS-CoV-2 case notification rates, moderate lockdowns (HR 0·84, 95% CI 0·80–0·88; p<0·001), and full lockdowns (0·57, 0·54–0·60; p<0·001), remained independently associated with non-operation. Surgery beyond 12 weeks from diagnosis in patients without neoadjuvant therapy increased during lockdowns (374 [9·1%] of 4521 in light restrictions, 317 [10·4%] of 3646 in moderate lockdowns, 2001 [23·8%] of 11827 in full lockdowns), although there were no differences in resectability rates observed with longer delays. Interpretation Cancer surgery systems worldwide were fragile to lockdowns, with one in seven patients who were in regions with full lockdowns not undergoing planned surgery and experiencing longer preoperative delays. Although short-term oncological outcomes were not compromised in those selected for surgery, delays and non-operations might lead to long-term reductions in survival. During current and future periods of societal restriction, the resilience of elective surgery systems requires strengthening, which might include protected elective surgical pathways and long- term investment in surge capacity for acute care during public health emergencies to protect elective staff and services. Funding National Institute for Health Research Global Health Research Unit, Association of Coloproctology of Great Britain and Ireland, Bowel and Cancer Research, Bowel Disease Research Foundation, Association of Upper Gastrointestinal Surgeons, British Association of Surgical Oncology, British Gynaecological Cancer Society, European Society of Coloproctology, Medtronic, Sarcoma UK, The Urology Foundation, Vascular Society for Great Britain and Ireland, and Yorkshire Cancer Research.
Background: Surgery is the main modality of cure for solid cancers and was prioritised to continue during COVID-19 outbreaks. This study aimed to identify immediate areas for system strengthening by comparing the delivery of elective cancer surgery during the COVID-19 pandemic in periods of lockdown versus light restriction. Methods: This international, prospective, cohort study enrolled 20 006 adult (≥18 years) patients from 466 hospitals in 61 countries with 15 cancer types, who had a decision for curative surgery during the COVID-19 pandemic and were followed up until the point of surgery or cessation of follow-up (Aug 31, 2020). Average national Oxford COVID-19 Stringency Index scores were calculated to define the government response to COVID-19 for each patient for the period they awaited surgery, and classified into light restrictions (index 60). The primary outcome was the non-operation rate (defined as the proportion of patients who did not undergo planned surgery). Cox proportional-hazards regression models were used to explore the associations between lockdowns and non-operation. Intervals from diagnosis to surgery were compared across COVID-19 government response index groups. This study was registered at ClinicalTrials.gov, NCT04384926. Findings: Of eligible patients awaiting surgery, 2003 (10·0%) of 20 006 did not receive surgery after a median follow-up of 23 weeks (IQR 16-30), all of whom had a COVID-19-related reason given for non-operation. Light restrictions were associated with a 0·6% non-operation rate (26 of 4521), moderate lockdowns with a 5·5% rate (201 of 3646; adjusted hazard ratio [HR] 0·81, 95% CI 0·77-0·84; p<0·0001), and full lockdowns with a 15·0% rate (1775 of 11 827; HR 0·51, 0·50-0·53; p<0·0001). In sensitivity analyses, including adjustment for SARS-CoV-2 case notification rates, moderate lockdowns (HR 0·84, 95% CI 0·80-0·88; p<0·001), and full lockdowns (0·57, 0·54-0·60; p<0·001), remained independently associated with non-operation. Surgery beyond 12 weeks from diagnosis in patients without neoadjuvant therapy increased during lockdowns (374 [9·1%] of 4521 in light restrictions, 317 [10·4%] of 3646 in moderate lockdowns, 2001 [23·8%] of 11 827 in full lockdowns), although there were no differences in resectability rates observed with longer delays. Interpretation: Cancer surgery systems worldwide were fragile to lockdowns, with one in seven patients who were in regions with full lockdowns not undergoing planned surgery and experiencing longer preoperative delays. Although short-term oncological outcomes were not compromised in those selected for surgery, delays and non-operations might lead to long-term reductions in survival. During current and future periods of societal restriction, the resilience of elective surgery systems requires strengthening, which might include protected elective surgical pathways and long-term investment in surge capacity for acute care during public health emergencies to protect elective staff and services.